AH
NMRA icon

Addis & Hill’s Neumora Therapeutics NMRA Stock Holding History

Addis & Hill’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Hold
163,386
– – 0.15% 28
2026
Q1 		$319K Hold
163,386
– – 0.19% 26
2025
Q4 		$292K Hold
163,386
– – 0.18% 26
2025
Q3 		$291K Hold
163,386
– – 0.18% 26
2025
Q2 		$120K Hold
163,386
– – 0.08% 27
2025
Q1 		$163K Hold
163,386
– – 0.11% 28
2024
Q4 		$1.73M Sell
163,386
-136,614
-46% -$1.64M 1.28% 11
2024
Q3 		$3.96M Hold
300,000
– – 3.04% 9
2024
Q2 		$2.94M Sell
300,000
-14,821
-5% -$153K 2.45% 9
2024
Q1 		$4.19M Buy
+314,821
New +$5.09M 3.57% 7

Other funds holding NMRA

WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Addis & Hill's NMRA Position: Q2 2026 in Review

Addis & Hill held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 163,386 shares worth $278K. The position accounts for 0.15% of the portfolio, ranked #28.

Addis & Hill first reported a position in NMRA in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.19M in Q1 2024. 3 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Addis & Hill held 163,386 shares of Neumora Therapeutics worth $278K as of Q2 2026.
  • Addis & Hill left its Neumora Therapeutics share count unchanged in Q2 2026.
  • Neumora Therapeutics made up 0.15% of Addis & Hill's portfolio in Q2 2026, its #28 holding.
  • Addis & Hill first reported a position in Neumora Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Addis & Hill's Neumora Therapeutics position peaked at $4.19M in Q1 2024.
  • 3 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Addis & Hill's 13F filing for Q2 2026, filed 7 Jul 2026.